NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 565.60 DKK | +2.59% |
|
-5.22% | -10.06% |
| Jan. 03 | New Year, Soft Start |  |
| Jan. 03 | BNP Paribas Exane Cuts Novo Nordisk PT, Maintains at Outperform | MT |
Evolution of the Average Target: Novo Nordisk A/S
Evolution of the Target Price: Novo Nordisk A/S
Changes in Analyst Recommendations: Novo Nordisk A/S
85ced2b6b64f047533f218bde0af8._PuaeBl_HrXcSwFukCoX4jB9WM8xWZgSTSvvl0Abmd0.lrDbNGMaS9mwAjBb-mJbt3xOAqJCbMxhLH3dxyIp75--zfEPWCBb15A7ag~c32d24ab0c1a6bc5cca8bd469ed09a43
More recommendations
| Analyst Opinion | 4m Revision of opinion | Divergence of analysts' opinions | Divergence of Target Price | Ecart obj. / dr | ||
|---|---|---|---|---|---|---|
| +50.68% | ||||||
| +34.69% | ||||||
| +16.53% | ||||||
| +16.54% | ||||||
| +28.22% | ||||||
| +13.70% | ||||||
| +29.60% | ||||||
| +14.34% | ||||||
| +18.54% | ||||||
| +16.58% | ||||||
| Average | +23.94% | |||||
| Weighted average by Cap. | +26.52% |
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
551.30DKK
Average target price
830.68DKK
Spread / Average Target
+50.68%
High Price Target
1,150.00DKK
Spread / Highest target
+108.60%
Low Price Target
515.00DKK
Spread / Lowest Target
-6.58%
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| BERNSTEIN RESEARCH | Florent Cespedes |
| JPMORGAN | Richard Vosser |
| UBS | Jo Walton |
| GOLDMAN SACHS | James Quigley |
| BERENBERG | Luisa Hector |
| Jyske Bank | |
| BNP Paribas | |
| JEFFERIES | Peter Welford |
| alphavalue | Abhishek Raval |
| Svenska Handelsbanken | |
| ODDO BHF | |
| DZ BANK | Elmar Kraus |
| BARCLAYS | Emily Field |
| DEUTSCHE BANK RESEARCH | Emmanuel Papadakis |
| AlphaValue/Baader Europe | |
| Argus | |
| Stifel Nicolaus | |
| BMO Capital | |
| Cantor Fitzgerald | |
| TD Cowen | |
| Berenberg Bank | |
| CREDIT SUISSE | Lorenzo Biasio |
| Morgan Stanley | |
| BNP Paribas Exane | |
| JPMorgan Chase | |
| Guggenheim | |
| Bryan, Garnier & Co. | |
| Deutsche Bank Securities | |
| DEUTSCHE BANK | Emmanuel Papadakis |
| Liberum Capital | |
| KEPLER CHEUVREUX | David Evans |
| HSBC | Stephen McGarry |
| INDEPENDENT RESEARCH | Tobias Gottschalt |
| BANK OF AMERICA (BOFA) | Sachin Jain |
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVO B Stock
- Consensus Novo Nordisk A/S
